Literature DB >> 26205579

Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin.

Nicholas Gulati1, Marianne B Løvendorf2,3, John R Zibert2, Kemal M Akat4, Neil Renwick4, Thomas Tuschl4, James G Krueger1.   

Abstract

Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions. MicroRNAs (miRNAs) are short non-coding RNAs that negatively regulate gene expression and have been implicated in various inflammatory skin diseases, but their role in DTH reactions is not well understood. We generated global miRNA expression profiles (using next-generation sequencing) of DPCP reactions in skin of seven healthy volunteers at 3, 14 and 120 days after challenge. Compared to placebo-treated sites, DPCP-challenged skin at 3 days (peak inflammation) had 127 miRNAs significantly deregulated. At 14 days (during resolution of inflammation), 43 miRNAs were deregulated and, at 120 days (when inflammation had completely resolved), six miRNAs were upregulated. While some miRNAs have been observed in psoriasis or atopic dermatitis, most of the deregulated miRNAs have not yet been studied in the context of skin biology or immunology. Across the three time points studied, many but not all miRNAs were uniquely expressed. As various miRNAs may influence T cell activation, this may indicate that the miRNAs exclusively expressed at different time points function to promote or resolve skin inflammation, and therefore, may inform on the paradoxical ability of DPCP to treat both autoimmune conditions (alopecia areata) and conditions of ineffective immunity (melanoma).
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  delayed-type hypersensitivity; diphencyprone; microRNA; next-generation sequencing

Mesh:

Substances:

Year:  2015        PMID: 26205579      PMCID: PMC4701645          DOI: 10.1111/exd.12813

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  30 in total

Review 1.  Alopecia areata: treatment of today and tomorrow.

Authors:  Pia Freyschmidt-Paul; Rudolf Happle; Kevin J McElwee; Rolf Hoffmann
Journal:  J Investig Dermatol Symp Proc       Date:  2003-06

2.  miR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer.

Authors:  Xuzhi Liu; Hanbing Shi; Bo Liu; Jianing Li; Yaxin Liu; Baiquan Yu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-05-02       Impact factor: 3.848

3.  MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG.

Authors:  Xiao-Ping Chen; You-Guo Chen; Jian-Yun Lan; Zong-Ji Shen
Journal:  Cancer Lett       Date:  2014-07-22       Impact factor: 8.679

4.  Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis.

Authors:  Marianne B Løvendorf; Hiroshi Mitsui; John R Zibert; Mads A Røpke; Markus Hafner; Beatrice Dyring-Andersen; Charlotte M Bonefeld; James G Krueger; Lone Skov
Journal:  Exp Dermatol       Date:  2015-03       Impact factor: 3.960

5.  The use of diphenylcyclopropenone in the treatment of recalcitrant warts.

Authors:  Jennifer A Upitis; Alfons Krol
Journal:  J Cutan Med Surg       Date:  2002-04-15       Impact factor: 2.092

6.  MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity.

Authors:  Thomas X Lu; Jochen Hartner; Eun-Jin Lim; Victoria Fabry; Melissa K Mingler; Eric T Cole; Stuart H Orkin; Bruce J Aronow; Marc E Rothenberg
Journal:  J Immunol       Date:  2011-08-17       Impact factor: 5.422

7.  Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation.

Authors:  Nan Jiang; Wen-Jie Chen; Jian-Wen Zhang; Chi Xu; Xian-Cheng Zeng; Tong Zhang; Yang Li; Guo-Ying Wang
Journal:  Oncotarget       Date:  2015-04-10

8.  14q32-encoded microRNAs mediate an oligometastatic phenotype.

Authors:  Abhineet Uppal; Sean C Wightman; Stephen Mallon; Go Oshima; Sean P Pitroda; Qingbei Zhang; Xiaona Huang; Thomas E Darga; Lei Huang; Jorge Andrade; Huiping Liu; Mark K Ferguson; Geoffrey L Greene; Mitchell C Posner; Samuel Hellman; Nikolai N Khodarev; Ralph R Weichselbaum
Journal:  Oncotarget       Date:  2015-02-28

9.  Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights.

Authors:  Nicholas Gulati; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Patricia Gilleaudeau; Mary Sullivan-Whalen; Joel Correa da Rosa; Inna Cueto; Hiroshi Mitsui; James G Krueger
Journal:  J Invest Dermatol       Date:  2014-04-21       Impact factor: 8.551

10.  MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1.

Authors:  Yixue Gu; Ye Cheng; Ying Song; Zhijie Zhang; Min Deng; Chengkun Wang; Guopei Zheng; Zhimin He
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

View more
  3 in total

1.  MicroRNA-934 is a novel primate-specific small non-coding RNA with neurogenic function during early development.

Authors:  Kanella Prodromidou; Ioannis S Vlachos; Maria Gaitanou; Georgia Kouroupi; Artemis G Hatzigeorgiou; Rebecca Matsas
Journal:  Elife       Date:  2020-05-27       Impact factor: 8.140

2.  Effects of metal nanoparticles on tight junction-associated proteins via HIF-1α/miR-29b/MMPs pathway in human epidermal keratinocytes.

Authors:  Jiali Yuan; Yue Zhang; Yuanbao Zhang; Yiqun Mo; Qunwei Zhang
Journal:  Part Fibre Toxicol       Date:  2021-03-19       Impact factor: 9.400

3.  Large-Scale Analysis of Drug Side Effects via Complex Regulatory Modules Composed of microRNAs, Transcription Factors and Gene Sets.

Authors:  Xiaodong Jia; Qing Jin; Xiangqiong Liu; Xiusen Bian; Yunfeng Wang; Lei Liu; Hongzhe Ma; Fujian Tan; Mingliang Gu; Xiujie Chen
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.